Molecular glues of the regulatory ChREBP/14-3-3 complex protect beta cells from glucolipotoxicity.

The Carbohydrate Response Element Binding Protein (ChREBP) is a glucose-responsive transcription factor (TF) with two major splice isoforms ( and {beta}). In chronic hyperglycemia and glucolipotoxicity, ChREBP-mediated ChREBP{beta} expression surges, leading to insulin-secreting {beta}-cell dedifferentiation and death. 14-3-3 binding to ChREBP results in cytoplasmic retention and suppression of transcriptional activity. Thus, small molecule-mediated stabilization of this protein-protein interaction (PPI) may be of therapeutic value. Here, we show that structure-based optimizations of a molecular glue compound led to potent ChREBP/14-3-3 PPI stabilizers with cellular activity. In primary human {beta}-cells, the most active compound retained ChREBP in the cytoplasm, and efficiently protected {beta}-cells from glucolipotoxicity while maintaining {beta}-cell identity. This study may thus not only provide the basis for the development of a unique class of compounds for the treatment of Type 2 Diabetes but also showcases an alternative molecular glue approach for achieving small molecule control of notoriously difficult to target TFs. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=106 SRC="FIGDIR/small/580675v2_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@18a17c8org.highwire.dtl.DTLVardef@11f6c0forg.highwire.dtl.DTLVardef@1ef4e63org.highwire.dtl.DTLVardef@34799_HPS_FORMAT_FIGEXP M_FIG C_FIG